Tivozanib fails in colorectal cancer; Aveo takes a dive
The hits keep coming for Aveo Pharmaceuticals Inc., as its once-daily VEGF receptor tyrosine kinase inhibitor failed another indication, this time colorectal cancer (CRC). The Cambridge, Mass.-based biotech’s already beaten-down stock fell 9 percent on news that the drug, tivozanib, foundered during an interim analysis in the Phase II BATON-CRC study, being carried out in partnership with Astellas Pharma Inc.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter